Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathyanarayanan, Vishwanath, Flowers, Christopher R., Iyer, Swaminathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392782/
https://www.ncbi.nlm.nih.gov/pubmed/32692628
http://dx.doi.org/10.1200/GO.20.00012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392782/
https://www.ncbi.nlm.nih.gov/pubmed/32692628
http://dx.doi.org/10.1200/GO.20.00012

Ejemplares similares